NxStage Hosts Panel Discussion on Home Nocturnal Hemodialysis at 2015 Annual Dialysis Conference

LAWRENCE, Mass., Feb. 2, 2015 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, will host an educational panel discussion today on home nocturnal hemodialysis therapy ("nocturnal") during the Annual Dialysis Conference (ADC) in New Orleans. A panel moderator will lead a discussion for dialysis providers on the NxStage System One™'s recent U.S. Food and Drug Administration's (FDA) clearance for nocturnal therapy, and its significant and wide-reaching clinical and lifestyle benefits. Panelists will highlight their applications of best demonstrated practices, offer insight on applying these tactics to build and develop nocturnal programs and expand access to this important therapy option for patients. Featured panelists are Dr. Robert Lockridge of Lynchburg Nephrology Physicians, Dr. Christopher Hoy of DCI Rubin Dialysis, and Lisa Koester, CNN-NP Renal Nurse Practitioner of Washington University School of Medicine, Renal Division.

In December 2014, the FDA cleared the company's System One to perform hemodialysis overnight while the patient is at home sleeping, known as nocturnal therapy. NxStage's System One is the first and only hemodialysis machine cleared by the FDA for this indication. A longer, overnight therapy allows greatly expanded flexibility in dialysis dose and schedule, better enabling physicians to match dialysis prescription to each patient's healthcare and lifestyle needs. By performing therapy while sleeping, patients are able to clear their schedules for other activities during the day.

"We've proven over the years that nocturnal therapy can drastically reduce the perceived time on dialysis," said Dr. Lockridge. "Through this panel discussion, I hope to assure my colleagues in nephrology that providing access to this important therapy option can make a significant difference in their patients' lives."

"These panelists have almost 70 years of experience collectively, and have blazed the trail for others with best demonstrated practices for nocturnal therapy," said NxStage President, Joe Turk. "ADC is a tremendous opportunity to finally promote what these leading nephrologists have practiced, and clinically tested, for some time. This first-of-its-kind clearance will provide patients with access to the enhanced clinical and lifestyle benefits made possible with nocturnal therapy."

For more information on the event and the System One, please visit www.nxstage.com.

Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.

About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact: 
Kristen K. Sheppard, Esq.
[email protected]

Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO

SOURCE NxStage Medical Inc.

Related Links

http://www.nxstage.com